WO2011033255A1 - (4-phenyl-piperidin-1-yl)-[5-1h-pyrazol-4yl)-thiophen-3-yl]-methanone compounds and their use - Google Patents

(4-phenyl-piperidin-1-yl)-[5-1h-pyrazol-4yl)-thiophen-3-yl]-methanone compounds and their use Download PDF

Info

Publication number
WO2011033255A1
WO2011033255A1 PCT/GB2010/001732 GB2010001732W WO2011033255A1 WO 2011033255 A1 WO2011033255 A1 WO 2011033255A1 GB 2010001732 W GB2010001732 W GB 2010001732W WO 2011033255 A1 WO2011033255 A1 WO 2011033255A1
Authority
WO
WIPO (PCT)
Prior art keywords
independently
compound according
present
compound
saturated aliphatic
Prior art date
Application number
PCT/GB2010/001732
Other languages
English (en)
French (fr)
Inventor
Scott Peter Webster
Jonathan Robert Seckl
Brian Robert Walker
Peter Ward
Thomas David Pallin
Hazel Joan Dyke
Trevor Robert Perrior
Original Assignee
The University Of Edinburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Edinburgh filed Critical The University Of Edinburgh
Priority to AU2010297068A priority Critical patent/AU2010297068B2/en
Priority to EP10755215.0A priority patent/EP2477983B1/en
Priority to KR1020127006255A priority patent/KR101702159B1/ko
Priority to ES10755215.0T priority patent/ES2540547T3/es
Priority to JP2012529335A priority patent/JP5779181B2/ja
Priority to IN2590DEN2012 priority patent/IN2012DN02590A/en
Priority to US13/395,963 priority patent/US8642621B2/en
Priority to DK10755215.0T priority patent/DK2477983T3/en
Priority to CA2772504A priority patent/CA2772504C/en
Publication of WO2011033255A1 publication Critical patent/WO2011033255A1/en
Priority to IL218315A priority patent/IL218315A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/12—Oxygen atoms acylated by aromatic or heteroaromatic carboxylic acids, e.g. cocaine

Definitions

  • the present invention pertains generally to the field of therapeutic compounds.
  • the present invention pertains to certain (4-phenyl-piperidin-1 -yl)- [5-(1 H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit
  • the present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 1 1 ⁇ -hydroxysteroid dehydrogenase type 1 ; to treat disorders that are ameliorated by the inhibition of
  • 11 ⁇ -hydroxysteroid dehydrogenase type 1 to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.
  • the metabolic syndrome which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.
  • Glucocorticoids are hormones that regulate a range of pathways involved in stress and metabolic signalling. They are antagonists of insulin action and impair insulin-dependent glucose uptake, increase lipolysis, and enhance hepatic gluconeogenesis. These effects are evident in Cushing's syndrome, which is caused by elevated circulating levels of glucocorticoids.
  • Cushing's syndrome are diverse and reflect the tissue distribution of glucocorticoid receptors in the body. They include a cluster of metabolic (central/visceral obesity, insulin resistance, hyperglycaemia, dyslipidaemia) and cardiovascular (hypertension)
  • Cushing's syndrome is reversible upon removal of the cause of glucocorticoid excess.
  • glucocorticoid activity is controlled at the tissue level by the intracellular conversion of active Cortisol and inactive cortisone by 11 ⁇ -hydroxysteroid dehydrogenases (see, e.g., Seckl et al., 2001). These enzymes exist in two distinct isoforms. 1 ⁇ -HSDI , which catalyses the reaction that activates cortisone, is expressed in liver, adipose tissue, brain, skeletal muscle, vascular smooth muscle and other organs, while, 1 1 -HSD2, which inactivates Cortisol, is predominantly expressed in the kidney.
  • 1 ⁇ -HSDI which catalyses the reaction that activates cortisone
  • mice lacking ⁇ ⁇ ⁇ -HSDI possess low triglycerides, increased HDL cholesterol, and increased apo-lipoprotein A-l levels (see, e.g., Morton et al., 2001), suggesting that inhibitors of ⁇ ⁇ ⁇ -HSDI may be of utility in the treatment of atherosclerosis.
  • the link between ⁇ ⁇ -HSDI and the metabolic syndrome has been strengthened by studies in transgenic mice and man. 11 ⁇ -HSDI knockout mice on two different genetic backgrounds are protected from dietary obesity (see, e.g., Morton et al., 2004), while administration of carbenoxolone to patients with type 2 diabetes enhances insulin sensitivity (see, e.g., Andrews et al., 2003).
  • mice with transgenic overexpression of 1 1 ⁇ -HSDI in adipose tissue have a more profound metabolic syndrome and obesity than mice with overexpression in liver (see, e.g., Paterson et al., 2004).
  • 11 ⁇ -HSDI activity is increased in adipose tissue, but enzyme activity is decreased in the liver (see, e.g., Rask et al., 2001).
  • 11 ⁇ -HSDI is highly expressed in regions important for cognition such as hippocampus, frontal cortex, and cerebellum (see, e.g., Moisan et al., 1990). Elevated Cortisol is associated with cognitive dysfunction, and glucocorticoids have a range of neurotoxic effects. 11 ⁇ -HSDI knockout mice are protected against age-related cognitive dysfunction (see, e.g., Yau et al., 2001), while administration of the ⁇ ⁇ -HSD inhibitor carbenoxolone has been shown to enhance cognitive function in elderly men and type 2 diabetics who have a selective impairment in verbal memory (see, e.g., Sandeep et al., 2004). Thus, 11 ⁇ -HSDI inhibitors are of potential therapeutic utility in the treatment of diseases such as Alzheimer's Disease, which are characterised by cognitive impairment.
  • the isozymes of 1 1 ⁇ -HSD are also expressed in the blood vessel wall (see, e.g., Walker et al., 1991 ; Christy et al., 2003).
  • ⁇ ⁇ -HSDI is expressed in vascular smooth muscle
  • 11 p-HSD2 is expressed in endothelial cells where it modulates endothelial- dependent vasodilation (see, e.g., Hadoke et al., 2001).
  • ⁇ ⁇ ⁇ -HSDI knockout mice have normal vascular function, but they exhibit enhanced angiogenesis in response to inflammation or ischaemia (see, e.g., Small et al., 2005). This offers therapeutic potential in the treatment of myocardial infarction, since inhibition of 11 ⁇ -HSDI may enhance revascularisation of ischaemic tissues.
  • Glucocorticoids are involved in the regulation of bone formation and skeletal
  • the inventors have discovered an especially preferred class of compounds, which inhibit 11 ⁇ -hydroxysteroid dehydrogenase type 1 (11 ⁇ -HSDI ), and which additionally have improved pharmacokinetic and/or microsomal stability properties, and which are useful in the treatment, control, and/or prevention of disorders (e.g., diseases) that are responsive to the inhibition of ⁇ ⁇ ⁇ -HSDl
  • One aspect of the invention pertains to certain (4-phenyl-piperidin-1-yl)-[5-(1 H-pyrazol-4- yl)-thiophen-3-yl]-methanone compounds (referred to herein as PPPT compounds), as described herein.
  • compositions e.g., a pharmaceutical composition
  • a composition comprising a PPPT compound, as described herein, and a pharmaceutically acceptable carrier or diluent.
  • 11 ⁇ -hydroxysteroid dehydrogenase type 1 (11 p-HSD1 ) function (e.g., in a cell), in vitro or in vivo, comprising contacting the cell with an effective amount of a PPPT compound, as described herein.
  • Another aspect of the present invention pertains to a method of treatment comprising administering to a subject in need of treatment a therapeutically-effective amount of a PPPT compound, as described herein, preferably in the form of a pharmaceutical composition.
  • Another aspect of the present invention pertains to a PPPT compound as described herein for use in a method of treatment of the human or animal body by therapy.
  • Another aspect of the present invention pertains to use of a PPPT compound, as described herein, in the manufacture of a medicament for use in treatment.
  • the treatment is treatment or prevention of a disorder (e.g., a disease) that is ameliorated by the inhibition of 1 1 ⁇ -hydroxysteroid dehydrogenase type 1 (1 1 p-HSD1 ).
  • a disorder e.g., a disease
  • the treatment is treatment or prevention of metabolic syndrome, which includes conditions such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease.
  • the treatment is treatment or prevention of a CNS disorder (e.g., a CNS disease) such as mild cognitive impairment and early dementia, including
  • Another aspect of the present invention pertains to a kit comprising
  • a PPPT compound as described herein, preferably provided as a pharmaceutical composition and in a suitable container and/or with suitable packaging;
  • Another aspect of the present invention pertains to a PPPT compound obtainable by a method of synthesis as described herein, or a method comprising a method of synthesis as described herein.
  • Another aspect of the present invention pertains to a PPPT compound obtained by a method of synthesis as described herein, or a method comprising a method of synthesis as described herein.
  • Another aspect of the present invention pertains to novel intermediates, as described herein, which are suitable for use in the methods of synthesis described herein.
  • Another aspect of the present invention pertains to the use of such novel intermediates, as described herein, in the methods of synthesis described herein.
  • One aspect of the present invention relates to certain (4-phenyl-pipehdin-1-yl)-[5-(1 H- pyrazol-4-yl)-thiophen-3-yl]-methanone compounds (for convenience, collectively referred to herein as "PPPT compounds”), which are related to the following compound:
  • -W is independently -H or -Y;
  • -Y is independently -Y 1 , -Y 2 , -Y 3 , -Y 4 , or -Y 5 ;
  • -Y 1 is independently -OH
  • -Y 2 is independently -Y 2 *, -Y 2B , or -Y 2C ;
  • -Y 3 is independently -Y 3A , -Y 3B , or -Y 3C ;
  • -Y 4 is independently -F, -CI, -Br, or -I;
  • each -R BB3 is independently -CN; and wherein: n is independently 0, 1 , 2, 3, 4, or 5;
  • -R B1 is independently -H or -R BB ;
  • -R B2 is independently -H or -R BB
  • each -R BB if present, is independently -R BB2 or -R BB3 .
  • each -R BB1 if present, is independently saturated aliphatic C 1-4 alkyl, and is optionally substituted with one or more substituents selected from -F, -OH, -OR BBB , -OCH 2 F, -OCHF 2 , -OCF 3 , -NH 2 , -NHR BBB , and -NR BBB 2 .
  • each -R BB1 if present, is independently saturated aliphatic C 1-4 alkyl, and is optionally substituted with one or more substituents selected from -F, -OH, -OR BBB , -OCH 2 F, -OCHF 2 , and -OCF 3 .
  • each -R BB1 if present, is independently saturated aliphatic C 1-4 alkyl, and is optionally substituted with one or more substituents selected from -F, -OH, and -OR BBB .
  • each -R BB1 is independently -Me, -Et, -nPr, -iPr, -nBu, -iBu, or -tBu.
  • each -R if present, is independently saturated aliphatic C -4 alkyl, and is optionally substituted with one or more substituents selected from -F, -CI, -OH, -OR zz , -OCH 2 F, -OCHF 2 , and -OCF 3 .
  • each -R is independently saturated aliphatic C 1-4 alkyl, and is optionally substituted with one or more substituents selected from -F, -CI, -OH, and -OR 22 .
  • each -R z is independently unsubstituted saturated aliphatic C ⁇ alkyl.
  • each -R 22 is independently -Me, -Et, -nPr, -iPr, -nBu, -iBu, or -tBu.
  • each -R z is independently saturated aliphatic C 1-6 alkyl, and is optionally substituted with one or more substituents selected from -F, -CI, -OH, -OR 22 , -OCH 2 F, -OCHF 2 , and -OCF 3 ; wherein each -R zz is independently saturated aliphatic C 1-4 alkyl.
  • each -R F if present, is independently -R z , -F, -CI, -Br, -I, -CF 3 , -OH, -OR z , -OCF 3 , or -CN.
  • each -R F if present, is independently -F, -CI, -Me, -Et, -OH, -OMe, -OEt, -CF 3l -OCF 3 , or -CN.
  • each -R F if present, is independently -F, -CI, -CF 3l -OMe, or -CN.
  • each -R z if present, is independently saturated aliphatic and is optionally substituted with one or more substituents selected from -F, -CI, -OH, -OR zz , -OCH 2 F, -OCHF 2 , and -OCF 3 .
  • each -R n is independently -Me, -Et, -nPr, -iPr, -nBu, -iBu, or -tBu.
  • the substantially purified form is at least 50% by weight, e.g., at least 60% by weight, e.g., at least 70% by weight, e.g., at least 80% by weight, e.g., at least 90% by weight, e.g., at least 95% by weight, e.g., at least 97% by weight, e.g., at least 98% by weight, e.g., at least 99% by weight.
  • substantially purified form refers to the compound in any
  • the substantially purified form refers to a mixture of stereoisomers, i.e., purified with respect to other compounds. In one embodiment, the substantially purified form refers to one
  • the substantially purified form refers to a mixture of enantiomers. In one embodiment, the substantially purified form refers to an equimolar mixture of enantiomers (i.e., a racemic mixture, a racemate). In one embodiment, the substantially purified form refers to one enantiomer, e.g., optically pure enantiomer.
  • the contaminants represent no more than 50% by weight, e.g., no more than 40% by weight, e.g., no more than 30% by weight, e.g., no more than 20% by weight, e.g., no more than 10% by weight, e.g., no more than 5% by weight, e.g., no more than 3% by weight, e.g., no more than 2% by weight, e.g., no more than 1% by weight.
  • the contaminants refer to other compounds, that is, other than stereoisomers or enantiomers. In one embodiment, the contaminants refer to other compounds and other stereoisomers. In one embodiment, the contaminants refer to other compounds and the other enantiomer.
  • the substantially purified form is at least 60% optically pure (i.e., 60% of the compound, on a molar basis, is the desired stereoisomer or enantiomer, and 40% is the undesired stereoisomer or enantiomer), e.g., at least 70% optically pure, e.g., at least 80% optically pure, e.g., at least 90% optically pure, e.g., at least 95% optically pure, e.g., at least 97% optically pure, e.g., at least 98% optically pure, e.g., at least 99% optically pure.
  • 60% optically pure i.e., 60% of the compound, on a molar basis, is the desired stereoisomer or enantiomer, and 40% is the undesired stereoisomer or enantiomer
  • at least 70% optically pure e.g., at least 80% optically pure, e.g., at least 90% optically pure, e
  • Certain compounds may exist in one or more particular geometric, optical, enantiomeric, diasteriomeric, epimeric, atropic, stereoisomeric, tautomeric, conformational, or anomeric forms, including but not limited to, cis- and trans-forms; E- and Z-forms; c-, t-, and r- forms; endo- and exo-forms; R-, S-, and meso-forms; D- and L-forms; d- and l-forms; (+) and (-) forms; keto-, enol-, and enolate-forms; syn- and anti-forms; synclinal- and anticlinal-forms; a- and ⁇ -forms; axial and equatorial forms; boat-, chair-, twist-, envelope-, and halfchair-forms; and combinations thereof, hereinafter collectively referred to as "isomers” (or "isomeric forms").
  • isomers are structural (or constitutional) isomers (i.e., isomers which differ in the connections between atoms rather than merely by the position of atoms in space).
  • a reference to a methoxy group, -OCH 3 is not to be construed as a reference to its structural isomer, a hydroxymethyl group, -CH 2 OH.
  • a reference to ortho-chlorophenyl is not to be construed as a reference to its structural isomer, meta-chlorophenyl.
  • a reference to a class of structures may well include structurally isomeric forms falling within that class (e.g., Ci. 7 alkyl includes n-propyl and iso-propyl; butyl includes n-, iso-, sec-, and tert-butyl; methoxyphenyl includes ortho-, meta-, and para-methoxyphenyl).
  • the above exclusion does not pertain to tautomeric forms, for example, keto-, enol-, and enolate-forms, as in, for example, the following tautomeric pairs: keto/enol (illustrated below), imine/enamine, amide/imino alcohol, amidine/amidine, nitroso/oxime,
  • H may be in any isotopic form, including H, 2 H (D), and 3 H (T); C may be in any isotopic form, including 12 C, 13 C, and 14 C; O may be in any isotopic form, including 16 0 and 18 0; and the like.
  • a reference to a particular compound includes all such isomeric forms, including mixtures (e.g., racemic mixtures) thereof.
  • Methods for the preparation (e.g., asymmetric synthesis) and separation (e.g., fractional crystallisation and chromatographic means) of such isomeric forms are either known in the art or are readily obtained by adapting the methods taught herein, or known methods, in a known manner.
  • Salts It may be convenient or desirable to prepare, purify, and/or handle a corresponding salt of the compound, for example, a pharmaceutically-acceptable salt.
  • suitable inorganic cations include, but are not limited to, alkali metal ions such as Na + and K + , alkaline earth cations such as Ca 2+ and Mg 2+ , and other cations such as ⁇ 3 .
  • suitable organic cations include, but are not limited to, ammonium ion (i.e., NH 4 + ) and substituted ammonium ions (e.g., NH 3 R + , NH 2 R 2 + , NHR 3 + , NR 4 + ).
  • suitable substituted ammonium ions are those derived from:
  • ethylamine diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids, such as lysine and arginine.
  • An example of a common quaternary ammonium ion is N(CH 3 ) 4 + .
  • a salt may be formed with a suitable anion.
  • suitable inorganic anions include, but are not limited to, those derived from the following inorganic acids: hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfurous, nitric, nitrous, phosphoric, and phosphorous.
  • Suitable organic anions include, but are not limited to, those derived from the following organic acids: 2-acetyoxybenzoic, acetic, ascorbic, aspartic, benzoic, camphorsulfonic, cinnamic, citric, edetic, ethanedisulfonic, ethanesulfonic, fumaric, glucheptonic, gluconic, glutamic, glycolic, hydroxymaleic, hydroxynaphthalene carboxylic, isethionic, lactic, lactobionic, lauric, maleic, malic, methanesulfonic, mucic, oleic, oxalic, palmitic, pamoic, pantothenic, phenylacetic, phenylsulfonic, propionic, pyruvic, salicylic, stearic, succinic, sulfanilic, tartaric, toluenesulfonic, and valeric.
  • a reference to a particular compound also includes salt forms thereof.
  • solvate is used herein in the conventional sense to refer to a complex of solute (e.g., compound, salt of compound) and solvent. If the solvent is water, the solvate may be conveniently referred to as a hydrate, for example, a mono-hydrate, a di-hydrate, a tri-hydrate, etc.
  • a reference to a particular compound also includes solvate and hydrate forms thereof.
  • chemically protected form is used herein in the conventional chemical sense and pertains to a compound in which one or more reactive functional groups are protected from undesirable chemical reactions under specified conditions (e.g., pH, temperature, radiation, solvent, and the like).
  • specified conditions e.g., pH, temperature, radiation, solvent, and the like.
  • well known chemical methods are employed to reversibly render unreactive a functional group, which otherwise would be reactive, under specified conditions.
  • one or more reactive functional groups are in the form of a protected or protecting group (also known as a masked or masking group or a blocked or blocking group).
  • a compound which has two nonequivalent reactive functional groups may be derivatized to render one of the functional groups "protected,” and therefore unreactive, under the specified conditions; so protected, the compound may be used as a reactant which has effectively only one reactive functional group.
  • the protected group may be "deprotected” to return it to its original functionality.
  • a hydroxy group may be protected as an ether (-OR) or an ester
  • the aldehyde or ketone group is readily regenerated by hydrolysis using a large excess of water in the presence of acid.
  • an amine group may be protected, for example, as an amide (-NRCO-R) or a urethane (-NRCO-OR), for example, as: a methyl amide (-NHCO-CH 3 ); a benzyl amide (-NHCH2C6H5); a benzyloxy amide (-NHCO-OCH 2 C 6 H 5 , -NH-Cbz); as a t-butoxy amide (-NHCO-OC(CH 3 ) 3 , -NH-Boc); a 2-biphenyl-2-propoxy amide
  • a carboxylic acid group may be protected as an ester for example, as. a Ci. 7 alkyl ester (e.g., a methyl ester; a t-butyl ester); a Ci. 7 haloalkyl ester (e.g., a C ytrihaloalkyl ester); a triC 1-7 alkylsilyl-C 1-7 alkyl ester; or a ester (e.g., a benzyl ester; a nitrobenzyl ester); or as an amide, for example, as a methyl amide.
  • a Ci. 7 alkyl ester e.g., a methyl ester; a t-butyl ester
  • a Ci. 7 haloalkyl ester e.g., a C ytrihaloalkyl ester
  • a triC 1-7 alkylsilyl-C 1-7 alkyl ester e.g.,
  • prodrug refers to a compound which, when metabolised (e.g., in vivo), yields the desired active compound.
  • the prodrug is inactive, or less active than the desired active compound, but may provide advantageous handling, administration, or metabolic properties.
  • some prodrugs are activated enzymatically to yield the active compound, or a compound which, upon further chemical reaction, yields the active compound (for example, as in ADEPT, GDEPT, LIDEPT, etc.).
  • the prodrug may be a sugar derivative or other glycoside conjugate, or may be an amino acid ester derivative.
  • compositions e.g., a pharmaceutical composition
  • a composition comprising a PPPT compound, as described herein, and a pharmaceutically acceptable carrier, diluent, or excipient.
  • compositions e.g., a pharmaceutical composition
  • a composition comprising admixing a PPPT compound, as described herein, and a pharmaceutically acceptable carrier, diluent, or excipient.
  • the PPPT compounds are useful, for example, in the treatment of disorders (e.g., diseases) that are ameliorated by the inhibition of 1 1 ⁇ -hydroxysteroid dehydrogenase type 1 ( ⁇ ⁇ ⁇ -HSDI ), as described herein.
  • One aspect of the present invention pertains to a method of inhibiting 1 1 -hydroxysteroid dehydrogenase type 1 in a cell, in vitro or in vivo, comprising contacting the cell with an effective amount of a PPPT compound, as described herein.
  • Suitable assays for determining 11 ⁇ -hydroxysteroid dehydrogenase type 1 inhibition are described herein and/or are known in the art. In one embodiment, the method is performed in vitro.
  • the method is performed in vivo.
  • the PPPT compound is provided in the form of a pharmaceutically acceptable composition.
  • Any type of cell may be treated, including but not limited to, adipose, lung, gastrointestinal (including, e.g., bowel, colon), breast (mammary), ovarian, prostate, liver (hepatic), kidney (renal), bladder, pancreas, brain, and skin.
  • adipose lung, gastrointestinal (including, e.g., bowel, colon), breast (mammary), ovarian, prostate, liver (hepatic), kidney (renal), bladder, pancreas, brain, and skin.
  • a sample of cells may be grown in vitro and a compound brought into contact with said cells, and the effect of the compound on those cells observed.
  • effect the morphological status of the cells (e.g., alive or dead, etc.) may be determined. Where the compound is found to exert an influence on the cells, this may be used as a prognostic or diagnostic marker of the efficacy of the compound in methods of treating a patient carrying cells of the same cellular type.
  • Another aspect of the present invention pertains to a PPPT compound, as described herein, for use in a method of treatment of the human or animal body by therapy.
  • Another aspect of the present invention pertains to use of a PPPT compound, as described herein, in the manufacture of a medicament for use in treatment.
  • the medicament comprises the PPPT compound.
  • Another aspect of the present invention pertains to a method of treatment comprising administering to a patient in need of treatment a therapeutically effective amount of a PPPT compound, as described herein, preferably in the form of a pharmaceutical composition.
  • the treatment is treatment or prevention of a disorder (e.g., a disease) that is ameliorated by the inhibition of ⁇ ⁇ ⁇ -hydroxysteroid dehydrogenase type 1.
  • a disorder e.g., a disease
  • the treatment is treatment or prevention of a disorder (e.g., a disease) that is characterised by one or more of: up-regulation of
  • the treatment is treatment or prevention of one or more of the following:
  • insulin resistance syndromes such as myotonic dystrophy, Prader Willi,
  • lipid disorders including dyslipidaemia
  • dementias such as Alzheimer's disease, multi-infarct dementia, dementia with Lewy bodies, fronto-temporal dementia (including Pick's disease), progressive supranuclear palsy, Korsakoff's syndrome, Binswanger's disease, HIV-associated dementia,
  • CJD Creutzfeldt-Jakob disease
  • Parkinson's disease Huntington's disease
  • Niemann-Pick disease type C normal pressure hydrocephalus
  • Down's syndrome Creutzfeldt-Jakob disease
  • depression and other affective disorders typical (melancholic) and atypical depression; dysthymia; post-partum depression; bipolar affective disorder; drug-induced affective disorders; anxiety; posttraumatic stress disorder; panic; phobias;
  • the treatment is treatment or prevention of one or more of the following:
  • the treatment is treatment or prevention of an adverse effect of glucocorticoids used to treat inflammatory diseases, such as asthma, chronic obstructive pulmonary disease, skin diseases, rheumatoid arthritis and other arthropathies, inflammatory bowel disease, and giant cell arthritis/polymyalgia
  • the treatment is treatment or prevention of metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease.
  • metabolic syndrome which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease.
  • the treatment is treatment or prevention of a CNS disorder (e.g., a CNS disease) such as mild cognitive impairment and early dementia, including Alzheimer's disease.
  • a CNS disorder e.g., a CNS disease
  • mild cognitive impairment and early dementia including Alzheimer's disease.
  • treatment pertains generally to treatment and therapy, whether of a human or an animal (e.g., in veterinary applications), in which some desired therapeutic effect is achieved, for example, the inhibition of the progress of the disorder, and includes a reduction in the rate of progress, a halt in the rate of progress, alleviation of symptoms of the disorder, amelioration of the disorder, and cure of the disorder.
  • Treatment as a prophylactic measure i.e., prophylaxis
  • prophylaxis is also included.
  • treatment includes the prophylaxis of metabolic syndrome, reducing the incidence of metabolic syndrome, alleviating the symptoms of metabolic syndrome, etc.
  • terapéuticaally-effective amount refers to that amount of a compound, or a material, composition or dosage form comprising a compound, which is effective for producing some desired therapeutic effect, commensurate with a reasonable benefit/risk ratio, when administered in accordance with a desired treatment regimen.
  • treatment includes combination treatments and therapies, in which two or more treatments or therapies are combined, for example, sequentially or simultaneously.
  • the compounds described herein may also be used in combination therapies, e.g., in conjunction with other agents.
  • treatments and therapies include, but are not limited to, chemotherapy (the administration of active agents, including, e.g., drugs, antibodies (e.g., as in immunotherapy), prodrugs (e.g., as in photodynamic therapy, GDEPT, ADEPT, etc.); surgery; radiation therapy; photodynamic therapy; gene therapy; and controlled diets.
  • One aspect of the present invention pertains to a compound as described herein, in combination with one or more (e.g., 1 , 2, 3, 4, etc.) additional therapeutic agents, as described below.
  • the particular combination would be at the discretion of the physician who would select dosages using his common general knowledge and dosing regimens known to a skilled practitioner.
  • the agents may be administered simultaneously or sequentially, and may be administered in individually varying dose schedules and via different routes.
  • the agents can be administered at closely spaced intervals (e.g., over a period of 5-10 minutes) or at longer intervals (e.g., 1 , 2, 3, 4 or more hours apart, or even longer periods apart where required), the precise dosage regimen being commensurate with the properties of the therapeutic agent(s).
  • agents i.e., the compound described here, plus one or more other agents
  • the agents may be formulated together in a single dosage form, or alternatively, the individual agents may be formulated separately and presented together in the form of a kit, optionally with instructions for their use.
  • agents/therapies that may be co-administered/combined with treatment with the PPPT compounds described herein include the following: (1) insulin and insulin analogues;
  • insulin sensitising agents for example: PPAR- ⁇ agonists; PPAR-a agonists; PPAR- ⁇ / ⁇ dual agonists; biguanides;
  • PACAP PACAP, PACAP mimetics, and PACAP receptor 3 agonists
  • agents that suppress hepatic glucose output such as metformin
  • agents designed to reduce the absorption of glucose from the intestine such as acarbose
  • anti-obesity agents including: orilistat, pramlintide, sibutramine, fenfluramine, phentermine, dexfenfluramine, cannabinoid CB1 receptor antagonists or inverse agonists such as rimonobant, ghrelin antagonists, oxyntomodulin, neuropeptide Y1 or Y5 antagonists, 5-HT 1B receptor agonists, 5-HT 2C receptor agonists, 5-HT 1 B /2c receptor dual agonists, melanocortin receptor agonists, and melanin-concentrating hormone receptor antagonists, bupropion, naltrexone, topiramate, growth hormone analogues, and ⁇ 3 agonists;
  • anti-dyslipidaemia agents including: HMG-CoA reductase inhibitors, PPAR-a agonists, PPAR-a/Y dual agonists, bile acid sequestrants, ileal bile acid absorption inhibitors, acyl CoA:cholesterol acyltransferase inhibitors, cholesterol absorption inhibitors, cholesterol ester transfer protein inhibitors, nicotinyl alcohol and its analogues, and anti-oxidants;
  • anti-inflammatory agents including: non-steroidal anti-inflammatory drugs such as aspirin; and steroidal anti-inflammatory agents such as hydrocortisone and
  • anti-hypertensive agents including: ⁇ -blockers such as atenolol and Inderal; calcium antagonists such as nifedipine; ACE inhibitors such as lisinopril, aptopril and captopril; angiotensin receptor antagonists such as candesartan, losartan and cilexetil; diuretic agents such as furosemide and benzthiazide; a-antagonists; centrally acting agents such as clonidine, methyl dopa, and indapamide; renin inhibitors; and vasodilators such as hydralazine;
  • ⁇ -blockers such as atenolol and Inderal
  • calcium antagonists such as nifedipine
  • ACE inhibitors such as lisinopril, aptopril and captopril
  • angiotensin receptor antagonists such as candesartan, losartan and cilexetil
  • diuretic agents such
  • dipeptidyl peptidase IV (DPP-IV) inhibitors such as sitagliptin and saxagliptin;
  • acetylcholinesterase inhibitors including: donezepil hydrochloride, rivastigmine and galanthamine;
  • NMDA receptor blockers including memantine hydrochloride
  • PPPT compounds described herein may also be used as cell culture additives to inhibit ⁇ ⁇ ⁇ -hydroxysteroid dehydrogenase type 1 ( ⁇ ⁇ ⁇ -HSDI), etc.
  • the PPPT compounds described herein may also be used as part of an in vitro assay, for example, in order to determine whether a candidate host is likely to benefit from treatment with the compound in question.
  • the PPPT compounds described herein may also be used as a standard, for example, in an assay, in order to identify other active compounds, other 11 ⁇ -hydroxysteroid dehydrogenase type 1 ( ⁇ ⁇ ⁇ -HSDI) inhibitors, etc. Kits
  • kits comprising (a) a PPPT compound as described herein, or a composition comprising a PPPT compound as described herein, e.g., preferably provided in a suitable container and/or with suitable packaging; and (b) instructions for use, e.g., written instructions on how to administer the compound or composition.
  • the written instructions may also include a list of indications for which the active ingredient is a suitable treatment.
  • the PPPT compound or pharmaceutical composition comprising the PPPT compound may be administered to a subject by any convenient route of administration, whether systemically/peripherally or topically (i.e., at the site of desired action).
  • Routes of administration include, but are not limited to, oral (e.g., by ingestion); buccal; sublingual; transdermal (including, e.g., by a patch, plaster, etc.); transmucosal (including, e.g., by a patch, plaster, etc.); intranasal (e.g., by nasal spray); ocular (e.g., by eyedrops); pulmonary (e.g., by inhalation or insufflation therapy using, e.g., via an aerosol, e.g., through the mouth or nose); rectal (e.g., by suppository or enema); vaginal (e.g., by pessary); parenteral, for example, by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal,
  • the subject/patient may be a chordate, a vertebrate, a mammal, a placental mammal, a marsupial (e.g., kangaroo, wombat), a rodent (e.g., a guinea pig, a hamster, a rat, a mouse), murine (e.g., a mouse), a lagomorph (e.g., a rabbit), avian (e.g., a bird), canine (e.g., a dog), feline (e.g., a cat), equine (e.g., a horse), porcine (e.g., a pig), ovine (e.g., a sheep), bovine (e.g., a cow), a primate, simian (e.g., a monkey or ape), a monkey
  • a rodent e.g., a guinea pig, a
  • the subject/patient may be any of its forms of development, for example, a foetus.
  • the subject/patient is a human.
  • the PPPT compound While it is possible for the PPPT compound to be administered alone, it is preferable to present it as a pharmaceutical formulation (e.g., composition, preparation, medicament) comprising at least one PPPT compound, as described herein, together with one or more other pharmaceutically acceptable ingredients well known to those skilled in the art, including, but not limited to, pharmaceutically acceptable carriers, diluents, excipients, adjuvants, fillers, buffers, preservatives, anti-oxidants, lubricants, stabilisers, solubilisers, surfactants (e.g., wetting agents), masking agents, colouring agents, flavouring agents, and sweetening agents.
  • the formulation may further comprise other active agents, for example, other therapeutic or prophylactic agents.
  • the present invention further provides pharmaceutical compositions, as defined above, and methods of making a pharmaceutical composition comprising admixing at least one PPPT compound, as described herein, together with one or more other pharmaceutically acceptable ingredients well known to those skilled in the art, e.g., carriers, diluents, excipients, etc. If formulated as discrete units (e.g., tablets, etc.), each unit contains a predetermined amount (dosage) of the compound.
  • pharmaceutically acceptable pertains to compounds, ingredients, materials, compositions, dosage forms, etc., which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of the subject in question (e.g., human) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • Each carrier, diluent, excipient, etc. must also be “acceptable” in the sense of being compatible with the other ingredients of the formulation.
  • Suitable carriers, diluents, excipients, etc. can be found in standard pharmaceutical texts, for example, Remington's Pharmaceutical Sciences. 18th edition, Mack Publishing Company, Easton, Pa., 1990; and Handbook of Pharmaceutical Excipients. 5th edition, 2005.
  • the formulations may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the compound with a carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the compound with carriers (e.g., liquid carriers, finely divided solid carrier, etc.), and then shaping the product, if necessary.
  • the formulation may be prepared to provide for rapid or slow release; immediate, delayed, timed, or sustained release; or a combination thereof.
  • Formulations may suitably be in the form of liquids, solutions (e.g., aqueous, nonaqueous), suspensions (e.g., aqueous, non-aqueous), emulsions (e.g., oil-in-water, water-in-oil), elixirs, syrups, electuaries, mouthwashes, drops, tablets (including, e.g., coated tablets), granules, powders, losenges, pastilles, capsules (including, e.g., hard and soft gelatin capsules), cachets, pills, ampoules, boluses, suppositories, pessaries, tinctures, gels, pastes, ointments, creams, lotions, oils, foams, sprays, mists, or aerosols.
  • solutions e.g., aqueous, nonaqueous
  • suspensions e.g., aqueous, non-aqueous
  • emulsions
  • Formulations may suitably be provided as a patch, adhesive plaster, bandage, dressing, or the like which is impregnated with one or more compounds and optionally one or more other pharmaceutically acceptable ingredients, including, for example, penetration, permeation, and absorption enhancers. Formulations may also suitably be provided in the form of a depot or reservoir.
  • the compound may be dissolved in, suspended in, or admixed with one or more other pharmaceutically acceptable ingredients.
  • the compound may be presented in a liposome or other microparticulate which is designed to target the compound, for example, to blood components or one or more organs.
  • Formulations suitable for oral administration include liquids, solutions (e.g., aqueous, non-aqueous), suspensions (e.g., aqueous, non-aqueous), emulsions (e.g., oil-in-water, water-in-oil), elixirs, syrups, electuaries, tablets, granules, powders, capsules, cachets, pills, ampoules, boluses.
  • Formulations suitable for buccal administration include mouthwashes, losenges, pastilles, as well as patches, adhesive plasters, depots, and reservoirs.
  • Losenges typically comprise the compound in a flavored basis, usually sucrose and acacia or tragacanth.
  • Pastilles typically comprise the compound in an inert matrix, such as gelatin and glycerin, or sucrose and acacia.
  • Mouthwashes typically comprise the compound in a suitable liquid carrier.
  • Formulations suitable for sublingual administration include tablets, losenges, pastilles, capsules, and pills.
  • Formulations suitable for oral transmucosal administration include liquids, solutions (e.g., aqueous, non-aqueous), suspensions (e.g., aqueous, non-aqueous), emulsions (e.g., oil- in-water, water-in-oil), mouthwashes, losenges, pastilles, as well as patches, adhesive plasters, depots, and reservoirs.
  • solutions e.g., aqueous, non-aqueous
  • suspensions e.g., aqueous, non-aqueous
  • emulsions e.g., oil- in-water, water-in-oil
  • mouthwashes e.g., gluges, pastilles, as well as patches, adhesive plasters, depots, and reservoirs.
  • Formulations suitable for non-oral transmucosal administration include liquids, solutions (e.g., aqueous, non-aqueous), suspensions (e.g., aqueous, non-aqueous), emulsions (e.g., oil-in-water, water-in-oil), suppositories, pessaries, gels, pastes, ointments, creams, lotions, oils, as well as patches, adhesive plasters, depots, and reservoirs.
  • solutions e.g., aqueous, non-aqueous
  • suspensions e.g., aqueous, non-aqueous
  • emulsions e.g., oil-in-water, water-in-oil
  • suppositories e.g., pessaries, gels, pastes, ointments, creams, lotions, oils, as well as patches, adhesive plasters, depots, and reservoirs.
  • Formulations suitable for transdermal administration include gels, pastes, ointments, creams, lotions, and oils, as well as patches, adhesive plasters, bandages, dressings, depots, and reservoirs. Tablets may be made by conventional means, e.g., compression or moulding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the compound in a free-flowing form such as a powder or granules, optionally mixed with one or more binders (e.g., povidone, gelatin, acacia, sorbitol, tragacanth, hydroxypropylmethyl cellulose); fillers or diluents (e.g., lactose, microcrystalline cellulose, calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc, silica); disintegrants (e.g., sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose); surface-active or dispersing or wetting agents (e.g., sodium lauryl sulfate); preservatives (e.g., methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, sorbic acid); flavours, flavour enhancing agents, and sweeteners.
  • binders
  • Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the compound therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile.
  • Tablets may optionally be provided with a coating, for example, to affect release, for example an enteric coating, to provide release in parts of the gut other than the stomach.
  • Ointments are typically prepared from the compound and a paraffinic or a water-miscible ointment base.
  • Creams are typically prepared from the compound and an oil-in-water cream base.
  • the aqueous phase of the cream base may include, for example, at least about 30% w/w of a polyhydric alcohol, i.e., an alcohol having two or more hydroxyl groups such as propylene glycol, butane-1 ,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol and mixtures thereof.
  • the topical formulations may desirably include a compound which enhances absorption or penetration of the compound through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogues.
  • Emulsions are typically prepared from the compound and an oily phase, which may optionally comprise merely an emulsifier (otherwise known as an emulgent), or it may comprise a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil.
  • an emulsifier also known as an emulgent
  • a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabiliser. It is also preferred to include both an oil and a fat.
  • the emulsifier(s) with or without stabiliser(s) make up the so-called emulsifying wax
  • the wax together with the oil and/or fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
  • Suitable emulgents and emulsion stabilisers include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate and sodium lauryl sulfate.
  • suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the compound in most oils likely to be used in pharmaceutical emulsion formulations may be very low.
  • the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers.
  • Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.
  • Formulations suitable for intranasal administration, where the carrier is a liquid include, for example, nasal spray, nasal drops, or by aerosol administration by nebuliser, include aqueous or oily solutions of the compound.
  • Formulations suitable for intranasal administration include, for example, those presented as a coarse powder having a particle size, for example, in the range of about 20 to about 500 microns which is administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
  • Formulations suitable for pulmonary administration include those presented as an aerosol spray from a pressurised pack, with the use of a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichoro-tetrafluoroethane, carbon dioxide, or other suitable gases.
  • Formulations suitable for ocular administration include eye drops wherein the compound is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the compound.
  • Formulations suitable for rectal administration may be presented as a suppository with a suitable base comprising, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols, for example, cocoa butter or a salicylate; or as a solution or suspension for treatment by enema.
  • Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the compound, such carriers as are known in the art to be appropriate.
  • Formulations suitable for parenteral administration include aqueous or non-aqueous, isotonic, pyrogen-free, sterile liquids (e.g., solutions, suspensions), in which the compound is dissolved, suspended, or otherwise provided (e.g., in a liposome or other microparticulate).
  • Such liquids may additionally contain other pharmaceutically acceptable ingredients, such as anti-oxidants, buffers, preservatives, stabilisers, bacteriostats, suspending agents, thickening agents, and solutes which render the formulation isotonic with the blood (or other relevant bodily fluid) of the intended recipient.
  • excipients include, for example, water, alcohols, polyols, glycerol, vegetable oils, and the like.
  • suitable isotonic carriers for use in such formulations include Sodium Chloride Injection, Ringer's Solution, or Lactated Ringer's Injection.
  • the concentration of the compound in the liquid is from about 1 ng/mL to about 10 pg/mL, for example from about 10 ng/mL to about 1 pg/mL
  • the formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets.
  • PPPT compounds can vary from patient to patient. Determining the optimal dosage will generally involve the balancing of the level of therapeutic benefit against any risk or deleterious side effects.
  • the selected dosage level will depend on a variety of factors including, but not limited to, the activity of the particular PPPT compound, the route of administration, the time of administration, the rate of excretion of the PPPT compound, the duration of the treatment, other drugs, compounds, and/or materials used in combination, the severity of the disorder, and the species, sex, age, weight, condition, general health, and prior medical history of the patient.
  • the amount of PPPT compound and route of administration will ultimately be at the discretion of the physician, veterinarian, or clinician, although generally the dosage will be selected to achieve local concentrations at the site of action which achieve the desired effect without causing substantial harmful or deleterious side-effects.
  • Administration can be effected in one dose, continuously or intermittently (e.g., in divided doses at appropriate intervals) throughout the course of treatment. Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the formulation used for therapy, the purpose of the therapy, the target cell(s) being treated, and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician, veterinarian, or clinician.
  • a suitable dose of the PPPT compound is in the range of about 10 yg to about 250 mg (more typically about 100 g to about 25 mg) per kilogram body weight of the subject per day.
  • the compound is a salt, an ester, an amide, a prodrug, or the like
  • the amount administered is calculated on the basis of the parent compound and so the actual weight to be used is increased proportionately.
  • Analytical Method 1 The system consisted of a Hewlett Packard HP1100 LC system and a Higgins Clipeus 5 ⁇ C18 100 x 3.0mm column maintained at 40°C. Detection was achieved using a Waters Quattro Micro triple quadrupole mass spectrometer (electrospray, positive ion and negative ion), a DAD UV detector and a Sedex ELS 85 evaporative light scattering detector.
  • Mobile Phase A 0.1 % aqueous formic acid.
  • Mobile Phase B 0.1% formic acid in MeOH.
  • Flow rate 1 mL/min Gradient: 0-1 min 15% B; 1-13 min 15-95% B; 13-20 min 95% B; 20-22 min 95-15% B; 22-25 min 15% B.
  • Analytical Method 2 The system consisted of a Waters Acquity UPLC system and an Acquity BEH C18 1.7 ⁇ 100 x 2.1 mm column, maintained at 40°C. Detection was achieved using a Waters Micromass ZQ2000 quadrupole mass spectrometer (electrospray, positive ion and negative ion), a PDA UV detector.
  • Mobile Phase A 0.1% aqueous formic acid
  • Mobile Phase B 0.1% formic acid in MeCN.
  • Flow rate 0.4 mL/min Gradient: 0-0.4 min 5% B; 0.4-6.0 min 5-95% B; 6-6.8 min 95% B; 6.8-7.0 min 95-5% B; 7-8 min 5% B.
  • the system consisted of a Waters Acquity UPLC system and a Higgins Clipeus 5 pm C18 100 x 3.0 mm column, maintained at 40°C. Detection was achieved using a Waters Micromass ZQ2000 quadrupole mass spectrometer (electrospray, positive ion and negative ion), a PDA UV detector.
  • Mobile Phase A 0.1% aqueous formic acid
  • Mobile Phase B 0.1% formic acid in MeOH.
  • Flow rate 1 mL/min Gradient: 0-1 min 15% B; 1-13 min 15-95% B; 13-20 min 95% B; 20-22 min 95-15% B; 22-25 min 15% B.
  • the system consisted of a Hewlett Packard 1050 LC system and a Luna 3 ⁇ C18(2) 30 x 4.6 mm column. Detection was achieved using a Finnigan AQA single quadrupole mass spectrometer (electrospray, positive ion), a UV diode array detector and a Sedex ELS 65 evaporative light scattering detector.
  • Mobile Phase A 0.1% aqueous formic acid
  • Mobile Phase B 0.1% formic acid in MeOH.
  • Flow rate 2 mL/min Gradient: 0-0.5 min 5% B; 0.5-4.5 min 5-95% B; 4.5-5 min 95% B; 5.5-6.0 min 95-5% B.
  • DAST Diethylaminosulphur trifluoride.
  • DIPEA Diisopropylethylamine
  • HATU (O- T-azabenzotriazol- -y -N.N.N'.N'-tetramethyluroniumhexafluoro-phosphate).
  • TFA Trifluoroacetic acid
  • 5-Bromo-thiophene-3-carboxylic acid methyl ester (6 g, 27 mmol) was dissolved in a mixture of DME (75 mL), IMS (25 mL) and water (12.5 mL).
  • Caesium carbonate (13.2 g, 40 mmol) and 4-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-pyrazole-1 -carboxylic acid tert-butyl ester (9.2 g, 31 mmol) were added and the mixture stirred under argon.
  • Lithium aluminium hydride (0.026 g, 0.7 mmol) was suspended in dry THF (1 mL) under a nitrogen atmosphere and cooled in an ice bath.
  • a solution of 4-(2-methoxycarbonyl- phenyl)-piperidine-1-carboxylic acid tert-butyl ester (0.27 g, 0.7 mmol) in dry THF (2 mL) was added drop wise and the reaction mixture stirred for 1 hour.
  • the reaction mixture was diluted with diethyl ether (5 mL) and quenched with hydrochloric acid (1 N, 5 mL).
  • Aluminium trichloride (15 g) was added portion wise and the mixture then heated at reflux for 0.5 hours. The mixture was then allowed to cool and poured over ice. The resulting solution was treated with sodium hydroxide until basic and the products extracted into ethyl acetate, dried over magnesium sulphate, filtered and the solvent removed by evaporation under vacuum. The residue was purified by silica chromatography eluting with a mixture of ethyl acetate and hexane. The fractions containing the desired products were combined and the solvent removed by evaporation to give a 4:1 mixture of the title compound and 1-benzyl-4-(4-chloro-phenyl)-4-methyl-piperidine which was used directly without further purification. Synthesis 39
  • SPA Scintillation Proximity Assay
  • HEK293 cells were stably transfected with a construct containing the full-length gene coding for the human 1 1 ⁇ -HSDI enzyme to create HEK293/1 1 ⁇ -HSDI cells.
  • Cells were routinely cultured in DMEM containing 10% calf foetal serum, 1 % glutamine, and 1 % penicillin and streptomycin. Prior to assay, cells were plated at 2 x 10 4 cells/well in 96-well poly-D-Lys coated flat-bottomed microplates and incubated in 5% C0 2 , 95% 0 2 at 37°C for 24 hours. The media in each well was removed immediately before assay.
  • CHO cells stably transfected with the full- length gene coding for human 1 1 p-HSD2 were used. Assays were carried out in 96-well microplates containing 1 x 10 5 cells/well. Controls and compounds were plated as above, so that the final D SO concentration in each well was 1 %. To initiate the assay, 90 ⁇ . of a solution of HAMS F-12 medium containing 1 % glutamine, 1 % penicillin and
  • the assay solutions were transferred to glass tubes and 20 ⁇ _ ethyl acetate added to each tube. Each tube was vortexed thoroughly and the upper layer containing the tritiated steroid transferred to a fresh glass tube.
  • the solvent was evaporated by placing the tubes in a heating block at 65°C under a stream of Nitrogen gas. 20 ⁇ _ ethanol was added to each of the dried samples and vortexed briefly. Each sample was applied to a silica TLC plate and the plate dried. The plate was placed vertically in a glass tank containing 92% chloroform : 8% ethanol and the solvent allowed to rise up the plate. The plate was dried, placed in an imaging cassette, and overlayed with a tritium imaging plate for 1-2 days. The amount of enzyme inhibition in each sample was determined by measuring the intensity of the substrate and product spots using a phosphoimager.
  • test or reference compound 4 ⁇ . was added to a well of a 24-well microplate and 0.5 mL of 4mM NADPH added. The plate was then transferred to a shaker for
  • Samples were analyzed by TSQ Quantum Discovery Tandem Mass Spectrometer and Surveyor Liquid Chromatogram (Thermo, Hemel-Hempstead, UK). 10 ⁇ . of each sample was injected in a mobile phase consisting of 60%:40% methanols mM ammonium acetate at a flow rate of 0.5 mL/minute.
  • the column used was a BDS hypersil, C18, 50 X 2.1 mm with a 5 pm particle size.
  • Each compound was tuned with a spray voltage of 3000 V and a capillary temperature of 300°C and values for tube lens, CID and product ions were determined.
  • the peak area for each compound was measured in triplicate for the 0 and 30 minute samples and the average of each was reported. The percentage remaining after 30 minutes was calculated as the average peak area of the sample after 30 minutes divided by the average peak area at 0 minutes. The RSD was 10% or lower for each compound.
  • pharmacokinetics of certain compounds were determined following intravenous (1 mg/kg) and oral (10 mg/kg) administration to male Sprague Dawley rats. Dosing solution was prepared by mixing each compound with 2% DMSO, 38% PEG-400 and 60% (0.9%) NaCI. Solutions were passed through 0.2 ⁇ filters prior to administration.
  • All of the compounds tested have an IC 5 o for 1 1 ⁇ -HSDI of less than about 10 ⁇ . Many of the compounds have an IC 50 for 11 ⁇ -HSDI of less than about 1 ⁇ . Many of the compounds have an IC 50 for 11 ⁇ -HSDI of less than about 500 nM.
  • the IC 50 ratio for 1 1 -HSD2 to 11 ⁇ -HSDI is at least about five or greater, and in many cases ten or greater.
  • data for some of the compounds is shown in the following table. Table 1
  • the following compounds have an IC 50 for 1 1 ⁇ -HSDI (HEK293) of less than or equal to 500 nM (0.5 ⁇ ): AA-01 , AA-02, AA-04, AA-05, AA-06, AA-07, AA-08, AA-09, AA-1 1 , AA-12, AA-13, AA-14, AA-15, AA-16, AA-18, AA-21 , AA-22, AA-23, AA-24, AA-25, AA-26, AA-27, AA-28, AA-29, AA-30, AA-31 , AA-33, AA-34, AA-36, AA-37, AA-38, AA-40, BB-03, BB-04, BB-05, BB-07, BB-08, BB-09, BB-12, BB-14 and BB-15.
  • the following compounds have an IC S0 for 1 1 ⁇ -HSDI (HEK293) of more than 500 nM (0.5 ⁇ ) and less than or equal to 1000 nM (1 ⁇ ): AA-03, AA-17, AA-32, AA-35, BB-01 , BB-06, BB-10, BB-1 1 and BB-13.
  • the following compounds have an IC 50 for 1 1 ⁇ -HSDI (HEK293) of more than 1000 nM (1.0 ⁇ ) and less than or equal to 10 ⁇ : AA-10, AA-19, AA-20, AA-39, AA-41 and BB-02.
  • Metabolism of compounds typically generates polar species that are cleared more rapidly from the body than the parent compound.
  • One method of increasing the concentration of a compound in the body is to slow down its metabolism in the liver (and gut) and hence reduce its clearance from the body. If a compound is administered orally and metabolism in the gut wall occurs, slowing the metabolism of a compound may also increase its absorption through the intestine leading to increased oral bioavailability.
  • Increasing the metabolic stability and lowering the clearance of a compound is desirable since it helps to maintain levels of the compound in the body and can prolong the duration of action of the compound.
  • Incubation of compounds with human liver microsomes is commonly used to predict the metabolism of compounds in vivo. Compounds with high microsomal stability are generally favoured since this often correlates with an improved pharmacokinetic profile in vivo.
  • microsomal stability assays The majority of the PPPT compounds tested in human microsomal stability assays have high microsomal stability (61-100% parent compound remaining). Fewer compounds have moderate microsomal stability (31-60% parent compound remaining) and fewer still have low microsomal stability (0-30%).
  • %Bioavailability 0-10% +; 11-30% ++; 31-100% +++
  • the bioavailability (%F) in rats of the majority of the PPPT compounds tested is greater than 30%.
  • RNA expression in rat forebrain localization in hypothalamus, hippocampus, and cortex," Endocrinology, Vol. 127, pp. 1450-1455.
  • tissue-specific amplifier of glucocorticoid action Endocrinology, Vol. 142, pp. 1371-1376.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
PCT/GB2010/001732 2009-09-16 2010-09-14 (4-phenyl-piperidin-1-yl)-[5-1h-pyrazol-4yl)-thiophen-3-yl]-methanone compounds and their use WO2011033255A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2010297068A AU2010297068B2 (en) 2009-09-16 2010-09-14 (4-phenyl-piperidin-1-yl)-[5-1H-pyrazol-4yl)-thiophen-3-yl]-methanone compounds and their use
EP10755215.0A EP2477983B1 (en) 2009-09-16 2010-09-14 (4-phenyl-piperidin-1-yl)-[5-1h-pyrazol-4yl)-thiophen-3-yl]-methanone compounds and their use
KR1020127006255A KR101702159B1 (ko) 2009-09-16 2010-09-14 （４―페닐―피페리딘―1―일）―［５―（1ｈ―피라졸―４―일）―티오펜―３―일］―메탄온 화합물 및 그의 용도
ES10755215.0T ES2540547T3 (es) 2009-09-16 2010-09-14 Compuestos de (4-fenil-piperidin-1-il)-[5-(1H-pirazol-4-il)-tiofen-3-il]-metanona y su uso
JP2012529335A JP5779181B2 (ja) 2009-09-16 2010-09-14 （４−フェニル−ピペリジン−１−イル）−［５−（１ｈ−ピラゾール−４−イル）−チオフェン−３−イル］−メタノン化合物及びそれらの使用
IN2590DEN2012 IN2012DN02590A (en10) 2009-09-16 2010-09-14
US13/395,963 US8642621B2 (en) 2009-09-16 2010-09-14 (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and their use
DK10755215.0T DK2477983T3 (en) 2009-09-16 2010-09-14 (4-phenyl-piperidin-1-yl) - [5-1H-pyrazol-4-yl) -thiophene-3-yl] -METHANONFORBINDELSER AND THEIR USE
CA2772504A CA2772504C (en) 2009-09-16 2010-09-14 (4-phenyl-piperidin-1-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and their use
IL218315A IL218315A (en) 2009-09-16 2012-02-26 Compounds (4-phenyl-piperidine-1-yl) - [5-1 h- pyrazole-4-yl) -thiophene-3-yl] -methane and their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24282509P 2009-09-16 2009-09-16
US61/242,825 2009-09-16

Publications (1)

Publication Number Publication Date
WO2011033255A1 true WO2011033255A1 (en) 2011-03-24

Family

ID=42946621

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/001732 WO2011033255A1 (en) 2009-09-16 2010-09-14 (4-phenyl-piperidin-1-yl)-[5-1h-pyrazol-4yl)-thiophen-3-yl]-methanone compounds and their use

Country Status (11)

Country Link
US (1) US8642621B2 (en10)
EP (1) EP2477983B1 (en10)
JP (1) JP5779181B2 (en10)
KR (1) KR101702159B1 (en10)
AU (1) AU2010297068B2 (en10)
CA (1) CA2772504C (en10)
DK (1) DK2477983T3 (en10)
ES (1) ES2540547T3 (en10)
IL (1) IL218315A (en10)
IN (1) IN2012DN02590A (en10)
WO (1) WO2011033255A1 (en10)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011135276A1 (en) * 2010-04-29 2011-11-03 The University Of Edinburgh 3, 3 -disubstituted- ( 8 - aza - bicyclo [3.2.1] oct- 8 - yl) -[5- (1h - pyrazol - 4 -yl) -thiophen-3 -yl] methanones as inhibitors of 11 (beta) -hsd1
US8299063B2 (en) 2008-03-13 2012-10-30 The University Of Edinburgh Amido-thiophene compounds and their use
US8362008B2 (en) 2007-12-12 2013-01-29 The University Of Edinburgh Amido-thiophene compounds and their use as 11-beta-HSD1 inhibitors
US8642621B2 (en) 2009-09-16 2014-02-04 The University Of Edinburgh (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and their use
WO2014152013A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
WO2014125233A3 (fr) * 2013-02-14 2014-10-09 Galderma Research & Development Procédé de synthèse de 4-piperidin-4-yl-benzène-1,3-diol et de ses sels et nouveau composé 4-(2,4-dihydroxy-phényl)-4-hydroxy-piperidine-1-carboxylate de tert-butyle
US9777010B2 (en) 2014-04-30 2017-10-03 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparation and use
US9926271B2 (en) 2013-03-14 2018-03-27 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
EP3976186A1 (en) * 2019-05-24 2022-04-06 Sage Therapeutics, Inc. Compounds, compositions, and methods of use
WO2022094668A1 (en) * 2020-11-06 2022-05-12 Actinogen Medical Limited Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof
WO2022115620A1 (en) * 2020-11-25 2022-06-02 Sage Therapeutics, Inc. 4-fluoro-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and similar compounds as cyp46a1 inhibitors for the treatment of neurodegenerative disorders
EP4037684A4 (en) * 2019-09-30 2023-11-01 Actinogen Medical Limited COGNITIVE MEDICINAL TREATMENTS

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017083795A1 (en) 2015-11-13 2017-05-18 Pietro Paolo Sanna Methods and compositions for treating alcohol use disorders
CN112028739A (zh) * 2019-06-04 2020-12-04 湖北大学 邻二卤代芳烃化合物功能化的方法
WO2024172156A1 (ja) * 2023-02-16 2024-08-22 国立大学法人東海国立大学機構 ブラシノステロイド様活性を有する化合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003044009A1 (en) * 2001-11-22 2003-05-30 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US20060111366A1 (en) * 2003-04-11 2006-05-25 Novo Nordisk A/S Pharmaceutical use of substituted amides
WO2009112845A1 (en) 2008-03-13 2009-09-17 The University Of Edinburgh Amido-thiophene compounds and their use
WO2010023161A1 (en) 2008-08-25 2010-03-04 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087631A (en) 1990-12-18 1992-02-11 Glaxo Inc. Oxathi(SIV)azol-5-one compounds
AR011913A1 (es) 1997-03-06 2000-09-13 Yamano Masaki Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos.
US6303593B1 (en) 1999-03-02 2001-10-16 Merck & Co., Inc. 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
SE0202430D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
EP1787982B1 (en) * 2003-04-11 2010-05-12 High Point Pharmaceuticals, LLC 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds
GB0325745D0 (en) 2003-11-05 2003-12-10 Astrazeneca Ab Chemical compounds
GB0326029D0 (en) 2003-11-07 2003-12-10 Astrazeneca Ab Chemical compounds
CN101001860A (zh) 2004-06-09 2007-07-18 霍夫曼-拉罗奇有限公司 杂环抗病毒化合物
WO2006132197A1 (ja) 2005-06-07 2006-12-14 Shionogi & Co., Ltd. I型11βヒドロキシステロイド脱水素酵素阻害活性を有するヘテロ環化合物
JP2009519218A (ja) 2005-11-03 2009-05-14 エスジーエックス ファーマシューティカルズ、インコーポレイテッド ピリミジニル−チオフェンキナーゼモジュレータ
US7645773B2 (en) 2006-01-18 2010-01-12 Hoffmann-La Roche Inc. Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase
BRPI0708353A8 (pt) * 2006-02-28 2017-09-19 Dart Neuroscience Cayman Ltd Compostos terapêuticos
ATE509921T1 (de) 2006-06-08 2011-06-15 Lilly Co Eli Substituierte carbonsäureamide als antagonisten des gruppe-i-metabotropen rezeptors
WO2008011453A2 (en) 2006-07-20 2008-01-24 Amgen Inc. SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1
GB0724251D0 (en) 2007-12-12 2008-02-06 Univ Edinburgh Therapeutic compounds and their use
US20100022590A1 (en) 2008-01-17 2010-01-28 Biovitrum Ab (Publ.) Novel compounds
WO2010146338A1 (en) 2009-06-15 2010-12-23 The University Of Edinburgh Amido-isothiazole compounds and their use as inhibitors of 11beta-hsd1 for the treatment of metabolic syndrome and related disorders
CA2772504C (en) 2009-09-16 2017-10-24 The University Of Edinburgh (4-phenyl-piperidin-1-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and their use
JP5899202B2 (ja) 2010-04-29 2016-04-06 ザ ユニバーシティ オブ エディンバラ １１β−ＨＳＤ１の阻害剤としての３，３−二置換−（８−アザ−ビシクロ［３．２．１］オクタ−８−イル）−［５−（１Ｈ−ピラゾール−４−イル）−チオフェン−３−イル］−メタノン類

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003044009A1 (en) * 2001-11-22 2003-05-30 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US20060111366A1 (en) * 2003-04-11 2006-05-25 Novo Nordisk A/S Pharmaceutical use of substituted amides
WO2009112845A1 (en) 2008-03-13 2009-09-17 The University Of Edinburgh Amido-thiophene compounds and their use
WO2010023161A1 (en) 2008-08-25 2010-03-04 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
"Reminoton's Pharmaceutical Sciences, 18th edition,", 1990, MACK PUBLISHING COMPANY
ANDREWS, R.C. ET AL.: "Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes", J. CLIN. ENDOCRINOL. METAB., vol. 88, 2003, pages 285 - 291
BERGE ET AL.: "Pharmaceutically Acceptable Salts", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
CHRISTY, C. ET AL.: "Glucocorticoid action in mouse aorta; localisation of 11 ?-hydroxysteroid dehydrogenase type 2 and effects on responses to glucocorticoids in vitro", HYPERTENSION, vol. 42, 2003, pages 580 - 587
COOPER, M.S ET AL.: "Expression and functional consequences of 11 ?-hydroxysteroid dehydrogenase activity in human bone", BONE, vol. 27, 2000, pages 375 - 381
HADOKE, P.W.F. ET AL.: "Endothelial cell dysfunction in mice after transgenic knockout of type 2, but not type 1, 1113-hydroxysteroid dehydrogenase", CIRCULATION, vol. 104, 2001, pages 2832 - 2837
KOTELEVTSEV, Y.V. ET AL.: "11?-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid inducible responses and resist hyperglycaemia on obesity and stress", PROC. NATL. ACAD. SCI., vol. 94, 1997, pages 14924 - 14929
MASUZAKI, H. ET AL.: "A Transgenic Model of Visceral Obesity and the Metabolic Syndrome", SCIENCE, vol. 294, 2001, pages 2166 - 2170
MOISAN, M. P. ET AL.: "11 beta-hydroxysteroid dehydrogenase bioactivity and messenger RNA expression in rat forebrain: localization in hypothalamus, hippocampus, and cortex", ENDOCRINOLOGY, vol. 127, 1990, pages 1450 - 1455
MORTON, N.M. ET AL.: "Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11 ?-hydroxysteroid dehydrogenase type 1 null mice", J. BIOL. CHEM., vol. 276, 2001, pages 41293 - 41300
MORTON, N.M. ET AL.: "Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11?-hydroxysteroid dehydrogenase type 1 deficient mice", DIABETES, vol. 53, 2004, pages 931 - 938
PATERSON, J.M. ET AL.: "Metabolic syndrome without obesity: hepatic overexpression of 1113-hydroxysteroid dehydrogenase type 1 in transgenic mice", PROC. NATL. ACAD. SCI., vol. 101, 2004, pages 7088 - 7093
RASK, E. ET AL.: "Tissue-specific dysregulation of cortisol metabolism in human obesity", J. CLIN. ENDOCRINOL. METAB., vol. 86, 2001, pages 1418 - 1421
RAUZ, S. ET AL.: "Expression and putative role of 11 beta-hydroxysteroid dehydrogenase isozymes within the human eye", INVESTIQATIVE OPTHALMOLOQY & VISUAL SCIENCE, vol. 42, 2001, pages 2037 - 2042
SANDEEP, T.C. ET AL.: "11?-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics", PROC. NATL. ACAD. SCI., vol. 101, 2004, pages 6734 - 6739
SECKL, J.R.; WALKER, B.R.: "11?-Hydroxysteroid dehydrogenase type 1 - a tissue-specific amplifier of glucocorticoid action", ENDOCRINOLOGY, vol. 142, 2001, pages 1371 - 1376
SMALL, G.R. ET AL.: "Preventing local regeneration of glucocorticoids by 11?-hydroxysteroid dehydrogenase type 1 enhances angiogenesis", PROC. NATL. ACAD. SCI., vol. 102, 2005, pages 12165 - 12170
T. GREEN; P. WUTS: "Protective Groups in Orqanic Synthesis; 4th Edition;", 2006, JOHN WILEY AND SONS
WALKER, B.R. ET AL.: "11(3-Hydroxysteroid dehydrogenase in vascular smooth muscle and heart: implications for cardiovascular responses to glucocorticoids", ENDOCRINOLOGY, vol. 129, 1991, pages 3305 - 3312
WALKER, B.R. ET AL.: "Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation", J. CLIN. ENDOCRINOL. METAB., vol. 80, 1995, pages 3155 - 3139
YAU, J.L.W. ET AL.: "Lack of tissue glucocorticoid reactivation in 11?-hydroxysteroid dehydrogenase type 1 knockout mice ameliorates age-related learning impairments", PROC. NATL. ACAD. SCI., vol. 98, 2001, pages 4716 - 4721

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8362008B2 (en) 2007-12-12 2013-01-29 The University Of Edinburgh Amido-thiophene compounds and their use as 11-beta-HSD1 inhibitors
US8299063B2 (en) 2008-03-13 2012-10-30 The University Of Edinburgh Amido-thiophene compounds and their use
US8614209B2 (en) 2008-03-13 2013-12-24 The University Of Edinburgh Amido-thiophene compounds and their use
US8642621B2 (en) 2009-09-16 2014-02-04 The University Of Edinburgh (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and their use
US9834549B2 (en) 2010-04-29 2017-12-05 The University Of Edinburgh 3,3-disubstituted-(8-aza-bicyclo[3.2.1]OCT-8-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11 (β)-HSD1
WO2011135276A1 (en) * 2010-04-29 2011-11-03 The University Of Edinburgh 3, 3 -disubstituted- ( 8 - aza - bicyclo [3.2.1] oct- 8 - yl) -[5- (1h - pyrazol - 4 -yl) -thiophen-3 -yl] methanones as inhibitors of 11 (beta) -hsd1
US9365564B2 (en) 2010-04-29 2016-06-14 The University Of Edinburgh 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11 (β)-HSD1
WO2014125233A3 (fr) * 2013-02-14 2014-10-09 Galderma Research & Development Procédé de synthèse de 4-piperidin-4-yl-benzène-1,3-diol et de ses sels et nouveau composé 4-(2,4-dihydroxy-phényl)-4-hydroxy-piperidine-1-carboxylate de tert-butyle
CN104995170A (zh) * 2013-02-14 2015-10-21 盖尔德马研究及发展公司 合成4-哌啶-4-基-苯-1,3-二醇及其盐以及新型化合物4-(2,4-二羟基-苯基)-4-羟基-哌啶-1-甲酸叔丁酯的方法
US9650337B2 (en) 2013-02-14 2017-05-16 Galderma Research & Development Method of synthesising 4-piperidin-4-yl-benzene-1,3-diol and the salts of same and novel compound tert-butyl 4-(2,4-dihydroxy-phenyl)-4-hydroxy-piperidine-1-carboxylate
EP2968304B1 (en) * 2013-03-14 2018-10-10 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
US10570148B2 (en) 2013-03-14 2020-02-25 The Trustees Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US9926271B2 (en) 2013-03-14 2018-03-27 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
US11919913B2 (en) 2013-03-14 2024-03-05 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
WO2014152013A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
US10273243B2 (en) 2013-03-14 2019-04-30 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
EP3495357A1 (en) * 2013-03-14 2019-06-12 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
US11028098B2 (en) 2013-03-14 2021-06-08 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
US10421720B2 (en) 2013-03-14 2019-09-24 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
US10787453B2 (en) 2013-03-14 2020-09-29 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
US9777010B2 (en) 2014-04-30 2017-10-03 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparation and use
US10913746B2 (en) 2014-04-30 2021-02-09 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparation and use
US10407433B2 (en) 2014-04-30 2019-09-10 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparation and use
US11649240B2 (en) 2014-04-30 2023-05-16 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparation and use
US10072016B2 (en) 2014-04-30 2018-09-11 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparation and use
EP3976186A1 (en) * 2019-05-24 2022-04-06 Sage Therapeutics, Inc. Compounds, compositions, and methods of use
TWI855081B (zh) * 2019-05-24 2024-09-11 美商賽吉醫療公司 化合物、組合物及使用方法
EP4037684A4 (en) * 2019-09-30 2023-11-01 Actinogen Medical Limited COGNITIVE MEDICINAL TREATMENTS
WO2022094668A1 (en) * 2020-11-06 2022-05-12 Actinogen Medical Limited Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof
CN116981461A (zh) * 2020-11-06 2023-10-31 射线质医疗有限公司 用于制备杂环甲酮化合物及其氮杂双环中间体的工艺
EP4240740A4 (en) * 2020-11-06 2024-12-11 Actinogen Medical Limited PROCESS FOR PREPARING HETEROCYCLIC METHANONE COMPOUNDS AND AZABICYCLO INTERMEDIATES THEREOF
WO2022115620A1 (en) * 2020-11-25 2022-06-02 Sage Therapeutics, Inc. 4-fluoro-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and similar compounds as cyp46a1 inhibitors for the treatment of neurodegenerative disorders

Also Published As

Publication number Publication date
IL218315A (en) 2014-12-31
AU2010297068A1 (en) 2012-04-12
KR101702159B1 (ko) 2017-02-02
CA2772504A1 (en) 2011-03-24
US20120172393A1 (en) 2012-07-05
JP5779181B2 (ja) 2015-09-16
US8642621B2 (en) 2014-02-04
CA2772504C (en) 2017-10-24
JP2013504613A (ja) 2013-02-07
AU2010297068B2 (en) 2015-10-01
EP2477983B1 (en) 2015-04-15
EP2477983A1 (en) 2012-07-25
IN2012DN02590A (en10) 2015-08-28
DK2477983T3 (en) 2015-06-29
IL218315A0 (en) 2012-04-30
ES2540547T3 (es) 2015-07-10
KR20120093161A (ko) 2012-08-22

Similar Documents

Publication Publication Date Title
EP2477983B1 (en) (4-phenyl-piperidin-1-yl)-[5-1h-pyrazol-4yl)-thiophen-3-yl]-methanone compounds and their use
EP2563780B1 (en) 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11(beta)-hsd1
EP2283004B1 (en) Amido-thiophene compounds and their use
US8362008B2 (en) Amido-thiophene compounds and their use as 11-beta-HSD1 inhibitors
WO2010146338A1 (en) Amido-isothiazole compounds and their use as inhibitors of 11beta-hsd1 for the treatment of metabolic syndrome and related disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10755215

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 218315

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2772504

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 20127006255

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13395963

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2012529335

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010297068

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2590/DELNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2010755215

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2010297068

Country of ref document: AU

Date of ref document: 20100914

Kind code of ref document: A